DAVID GRAHAM to Cardiovascular Diseases
This is a "connection" page, showing publications DAVID GRAHAM has written about Cardiovascular Diseases.
Connection Strength
0.262
-
Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002 Oct 28; 162(19):2197-202.
Score: 0.084
-
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. Arthritis Rheumatol. 2018 04; 70(4):537-546.
Score: 0.061
-
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 12 29; 375(26):2519-29.
Score: 0.056
-
Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009 Apr; 157(4):606-12.
Score: 0.033
-
Risk of low-dose aspirin: emphasis on outliers undermines the credibility of the conclusions. Aliment Pharmacol Ther. 2007 Feb 01; 25(3):345-6; author reply 346-7.
Score: 0.028